Skip to main content

Members

Members (89)

From across Europe and beyond, and from a variety of backgrounds, our members share many common goals. Our members’ diversity, expertise and openness to collaborate is our strength. Search our members list here. Filter using our search options. All members are encouraged to network and develop as a community that fosters collaboration. Find your match, share, engage and complement expertise.

Showing 21-30 of 89 members.

Gurila

Business enterprise
Home country
Georgia
Type of research activities
Applied research, Basic research, Experimental development
Fields of research
Economics and Business, Natural sciences, Medical and health sciences
Specialisation and expertise

We are the developer of an innovative technology for the production of a completely new highly effective active substance. These regenerating products are extremely effective in treatment of liver cirrhosis of various etiologies previously officially considered incurable (ascites goes away after 15 days, cirrhosis changes into fibrosis after 30-50 days, the period of complete hepatic regeneration is about 4 months). They are also effective against genital herpes virus (4-6 months), effective against hepatitis of various etiologies, including such as B, C, D ( viral load is reduced by half every 26 days, after a course of therapy, the virus is not detected in the blood, the patient ceases to be a virus carrier), drugs restore the liver in case of fatty hepatosis, pulmonary tuberculosis including MDR TB/ XDR TB (after 26 days an active form of stage 4 changes into stage 2-3 of latent form), lymphosarcoma, fibroma, myoma and pyelonephritis. The drugs prevent diabetic foot gangrene extremities. After the therapy patients no longer need previously recommended heart bypass surgery. The drug restores the function of the pancreas, and gives a complete restoration of long-term erectile dysfunction. The condition of patients with Alzheimer disease, Down's syndrome, encephalopathy, encephalitis and other diseases improves significantly without any side effects. The drugs have a strong antifibrotic effect, they dissolve scars on heart after myocardial infarction. Heart tissue completely regenerates within 6 months. This is only what we have studied so far.  We have strong assumptions that our medications can also effectively affect the activity of the COVID-19 coronavirus, as well as other viruses and infections. We are interested in partners and research of our drugs.

Language(s)
Russian, English, Spanish, French

PREDICTA S.A.

Business enterprise
Home country
Greece
Type of research activities
Applied research, Basic research
Fields of research
Economics and Business, Engineering and technology, Medical and health sciences
Specialisation and expertise

Consulting / Advisory Services areas: • Big Data Strategy design • Analytics Applications’ roadmap design • Wider Analytics technology infrastructure architectural design and implementation • Analytics’ neighboring domains roadmap design, i.e. Loyalty Scheme design and implementation, Marketing Automation/Campaign Management systems, Mobile Applications’ hosting/integrating technologies, … Professional Implementation Services Generic Analytics Applications & Methodologies: • Value-based Segmentation or/and RFM Analysis • Behavioral Segmentation Analysis • Strategic Segmentation Analysis • Next Best Offer Analysis • Cross/Up/Deep-Selling Propensity Modeling • Early Warnings on Signs of Customers’ Defection Analysis • Anti-Attrition / Churn Propensity Modeling • Social Network Analysis (SNA) • Forecasting Analysis • Credit Risk Modeling (PD, LGD, …) • Pre-Collections & Collections Modeling Industry-specific Analytical Solutions: • Total Enterprise Streamlined Customer Management for Next Best Action (NBA) • Performance Forecasting & Distribution Network Target Allocation • Customer Lending Optimization (CLO) • Geolocation Analytics for Cards’ transactions’ boosting, penetrating loyalty partners’ network (merchants) • Customer “Digitalization” Solution • Customer Onboarding Strategy Solution • Complaints Management via Text Analytics • Streamlined solution for IFRS9 Risk Regulatory Framework compliance and overall processes management.

Language(s)
English

Ragnarsdóttir, Guðrún, University of Iceland, School of Education

Higher education
Home country
Iceland
Type of research activities
Applied research, Basic research, Experimental development
Fields of research
Education, Sociology, Political science
Specialisation and expertise

Guðrún Ragnarsdóttir (gudrunr@hi.is) is an assistant professor. Her specialties lies within the upper secondary school level and her research interests include pedagogy, school development, professional development, political science, and school leadership.

Language(s)
English
The portal is now open.

Join this community of researchers, publish your member profile and team up for new collaboration opportunities.

Become a member